This year, hepatitis C drugs Epclusa and Vosevi have been filed by the MFDS in Korea. These items are expected to replace Sovaldi.

According to the industry on the 27th, Gilead's Vosevi (Sofosbuvir/Velpatasvir/Voxilaprevir) has recently been filed and will begin screening in earnest. Vosevi is expected to be a Pangenotypic DAA preparation that can be used in patients who fail to treat existing Direct-Acting Antiviral (DAA) drugs. AbbVie's Mavyret, a phangenotypic inhibitor, is now the market leading item. And, Mavyret is applicable to both chronic hepatitis C virus genotypes 1, 2, 3, 4, 5 and 6.

For Gilead's Sovaldi, it is only valid for type 1, 2, 3 and 4 and must be administered simulta